Stephen Mularz, DO
Gastroenterology · Hazard, KYNPI 1982018156
Payments from drug & device makers
Across 200 payments — averaging $22.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$751
- Johnson & Johnson$470
- Gilead$469
- Madrigal Pharmaceuticals$331
- Sanofi$226
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,41497%
- Education$1253%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $1,266 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $751 |
| Johnson & Johnson | 24 | $470 |
| Gilead | 14 | $469 |
| Madrigal Pharmaceuticals | 13 | $331 |
| Sanofi | 7 | $226 |
| La Jolla Pharmaceutical Company | 2 | $151 |
| AstraZeneca(2 entities) | 2 | $139 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $116 |
| Lilly USA, LLC | 5 | $88 |
| Phathom Pharmaceuticals, Inc. | 5 | $76 |
| Endogastric Solutions, Inc | 2 | $75 |
| Pfizer | 4 | $69 |
| Ardelyx, Inc. | 3 | $68 |
| Echosens North America, Inc. | 2 | $48 |
| Daiichi Sankyo Inc. | 2 | $27 |
| Olympus America Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Nestle Healthcare Nutrition Inc. | 1 | $23 |
| Novo Nordisk | 1 | $23 |
| Covidien LP | 1 | $18 |
| Ambu Inc. | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $16 |
| Merck | 1 | $14 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,539 in reported general payments places this provider in the 55th percentile of 207 gastroenterology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 87 | $9,546 |
| Colestipol Hcl | 134 | $4,069 |
| Ursodiol | 20 | $1,073 |
| Pantoprazole Sodium | 74 | $890 |
| Famotidine | 128 | $884 |
| ConstuloseLactulose | 15 | $606 |
| Lactulose | 12 | $462 |
| Spironolactone | 16 | $204 |
| Azathioprine | 15 | $192 |
| Nitroglycerin | 11 | $107 |
| Ciprofloxacin Hcl | 50 | $37 |
| Furosemide | 18 | $34 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Hazard
- Uday ShankarHazard$109K
- Gerald DrydenLouisville$3.5M
- Michael JonesCrestview Hills$1.9M
- Jens RosenauLexington$1.6M
- Matthew CaveLouisville$916K
- Deborah FlomenhoftLexington$905K
- Michael KreaseLouisville$694K
- Zahid SaeedCrestview Hills$442K
- Thomas AbellLouisville$375K
- Sunana SohiLouisville$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.